South Africa

  • Research/Demonstration Projects: South Africa hosted a site in the phase III iPrEx trial, and the open label extension of iPrEx in MSM and is hosting demonstration projects of daily oral PrEP in men who have sex with men and sex workers. PrEP is slated to be included in the PEPFAR-supported DREAMS initiative focused on young women and adolescent girls. Click here for a full list of planned, ongoing and completed research/demonstration projects.
  • Drug Registration: In November 2015 South Africa’s Medicines Control Council (MCC) approved the use of the fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for PrEP.
  • Policy/Regulatory: PrEP is included in the National Strategic Plan (NSP) for HIV, STIs and TB (2012-2016). The Southern African HIV Clinicians Society published a revised and expanded set of PrEP guidelines in early 2016 advising PrEP as a highly effective and safe prevention options for HIV prevention when combined with other combination prevention strategies. Click here for the National Policy on HIV Pre-exposure Prophylaxis (PrEP) and Test and Treat (T&T).
  • Advocacy: Prevention advocates are actively engaging with researchers and policy makers around revising PrEP guidelines, following the planned and ongoing PrEP demonstrations studies and discussing possible rollout plans. A recent opinion piece in the Mail & Guardian outlines advocates’ demands—a follow-up piece released after MCC announced its approval outlines what should come next. An AVAC Fellow hosted by TB-HIV Care Foundation is specifically working on these issues, as well as conducting community dialogues with a variety of stakeholders including sex-workers and young women. Through partnership work with CCISA, the ZAZI curriculum will have a new section specifically discussing the importance of new prevention options—including PrEP—for young women.
  • Country Close-Up: For a more detailed look at the landscape in South Africa, click here.

News Spotlight